Using nanoparticles to deliver cytokines for better cancer immunotherapy
Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles
['FUNDING_R01'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11050416
This study is exploring a new way to help your immune system fight cancer by using tiny particles to deliver special proteins that can boost your body's response, especially for those with metastatic ovarian cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11050416 on ClinicalTrials.gov |
What this research studies
This research investigates a novel method of delivering cytokines to enhance the immune response against cancer cells. By utilizing liposomal nanoparticles with controlled surface properties, the study aims to improve the targeting and effectiveness of cytokines like interleukin-12 (IL-12) in the tumor microenvironment. The approach focuses on increasing the infiltration of immune cells into tumors, potentially leading to better outcomes for patients undergoing immunotherapy. The research builds on previous findings that showed promising results in animal models, particularly in treating metastatic ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that are known to be resistant to current immunotherapy treatments.
Not a fit: Patients with non-cancerous conditions or those whose tumors are not responsive to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies with fewer side effects for patients.
How similar studies have performed: Other research has shown success with similar nanoparticle delivery systems in enhancing cancer treatment, indicating a promising avenue for this approach.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAMMOND, PAULA T — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: HAMMOND, PAULA T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy